Form 4: Provectus Biopharmaceuticals CEO Edward Pershing Reports Conversion of Convertible Note into Preferred Stock

CEO Edward Pershing reports the conversion of an 8% unsecured convertible promissory note into Series D-1 Convertible Preferred Stock of Provectus Biopharmaceuticals.

Summary

• On June 15, 2024, Edward Pershing, CEO of Provectus Biopharmaceuticals, reported a transaction involving the conversion of an 8% unsecured convertible promissory note into 47,190 shares of Series D-1 Convertible Preferred Stock.
• The conversion occurred at a price of $2.862 per share.
• The Series D-1 Preferred Stock is convertible into common stock at a rate of 10 shares of common stock per share of preferred stock.
• The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted.
• Following the reported transaction, Pershing directly owns 1,320,273 shares of common stock and 1,410,000 shares of Series D-1 Convertible Preferred Stock.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing an insider transaction. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

This Form 4 filing is a routine disclosure related to insider transactions and provides transparency to investors regarding the holdings and transactions of company executives. It is common for executives to hold convertible securities, and their conversion into common stock or preferred stock is a normal part of corporate finance.

Stakeholder Impact

• The conversion of the note into preferred stock may have a minor dilutive effect on existing common shareholders, depending on the subsequent conversion of the preferred stock into common stock.

Key Dates